DEMAREE JOHN 4
4 · Karyopharm Therapeutics Inc. · Filed Mar 1, 2021
Insider Transaction Report
Form 4
DEMAREE JOHN
Chief Commercial Officer
Transactions
- Award
Common Stock
2021-02-25+15,849→ 23,995 total - Award
Stock Option (right to buy)
2021-02-25+43,177→ 43,177 totalExercise: $14.56Exp: 2031-02-24→ Common Stock (43,177 underlying)
Footnotes (3)
- [F1]Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 25, 2022.
- [F2]The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 15,849 newly awarded RSUs and 8,146 shares of common stock, which include 646 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on October 31, 2020.
- [F3]This option was granted on February 25, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 25, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter.